Orphan Advantage Lead candidate AEM-28 carries FDA Orphan drug designation for HoFH, signaling potential for accelerated development paths, premium pricing, and exclusive market rights that can be attractive to a licensing partner seeking rare disease assets.

Licensing Opportunity As a clinical stage biotech with a single lead program, Capstone is well positioned to pursue joint development deals or licensing deals with larger pharma to fund trials, share risk, and access global commercialization capabilities for HoFH and related cardiovascular indications such as acute coronary syndrome, peripheral artery disease, and type 2 diabetes.

Indication Expansion Beyond HoFH, the company signals potential targeting of additional indications, enabling a multiple indications licensing strategy and a broader addressable market for AEM-28.

Strategic Partnerships With a small team and likely reliance on external development and manufacturing partners, Capstone can be a compelling partner for CROs, CDMOs, and contract regulatory services, offering a streamlined collaboration model for faster milestones.

Financial Signals Current revenue range suggests early stage commercialization or collaboration income; a structured deal with upfront milestone payments and royalties could align Capstone's needs with a partner’s scale while preserving upside.